Arcus Biosciences, Inc. (NYSE: RCUS) announced on February 18, 2025, that it has entered into an underwriting agreement with Goldman Sachs & Co. LLC and Leerink Partners LLC for the offering, issuance ...
Research analysts at Wedbush issued their FY2029 EPS estimates for shares of Arcus Biosciences in a note issued to investors ...
Marcus Stroman got his 2025 Spring Training with the New York Yankees back on track. The controversial right-hander was at ...
Another sign, called tendon xanthomata, leads to swelling in areas like your knuckles, the back of your ankle, and the ...
The pharma signed an agreement handing PE firm CD&R a 50% stake in its Capella unit. Elsewhere, Gilead and Ultragenyx secured ...
Precision BioSciences reports early PBGENE-HBV trial data showing safety and antiviral activity in chronic Hepatitis B patients, with more results expected in 2025.
The news comes on the heels of promising Phase I/Ib data, which point to the potential of casdatifan as a more effective ...
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo g ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback